D(1A) dopamine receptor
Cross-source identity
Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats D(1A) dopamine receptor as ChEMBL target CHEMBL265, mapped to UniProt P18901. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Why D(1A) dopamine receptor matters
D(1A) dopamine receptor is reviewed as D(1A) dopamine receptor (UniProt P18901); the current evidence base includes 24 approved drugs, 1241 compounds, and 284 assays, with lead potency reaching pChEMBL 10.1.
D(1A) dopamine receptor Sequence length is 446 aa.
Review this target as D(1A) dopamine receptor, mapped to UniProt P18901. Sequence length is 446 aa.
Protein source · UniProt accession via ChEMBL component mappingDisease relevance is not yet populated for this evidence card.
This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
ChEMBL target recordChEMBL currently tracks 24 approved drugs, 1241 compounds, and 284 assays for this target. The dominant activity type is KI. CHEMBL441618 is the current potency anchor at pChEMBL 10.1.
Use CHEMBL441618 as the tractability anchor when discussing potency (pChEMBL 10.1).
Activity source · ChEMBL 36 via Core EngineStart with the right source
Pick the first block or linked source that matches the review question in front of you.
Start with the review rationale when you need to explain why D(1A) dopamine receptor matters before drilling into raw source blocks.
Jump to Review RationaleGo back to the target snapshot when you need the naming and mapping contract behind UniProt P18901, not just the summarized rationale.
Open Protein ContextUse the target snapshot disease block when you need the disease program and supporting signals, not only the card summary.
Open Disease ContextSnapshot State
No project snapshot selected. Export uses the live evidence card state.
pChEMBL Activity Distribution
Top 5 Inhibitors (by pChEMBL)
| Structure | Compound | pChEMBL | Type | Phase |
|---|---|---|---|---|
|
|
No preferred name
CHEMBL441618
|
10.1 | Ki | — |
|
|
No preferred name
CHEMBL3763331
|
10.0 | Ki | — |
|
|
No preferred name
CHEMBL62
|
9.9 | Ki | — |
|
|
No preferred name
CHEMBL13632
|
9.6 | Ki | — |
|
|
No preferred name
CHEMBL1185
|
9.5 | Kd | Approved |
Approved Drugs
| Structure | Compound | First Approval |
|---|---|---|
|
|
ARIPIPRAZOLE
CHEMBL1112
|
2002 |
|
|
APOMORPHINE
CHEMBL53
|
2001 |
|
|
APOMORPHINE HYDROCHLORIDE
CHEMBL3187985
|
2001 |
|
|
ZOLMITRIPTAN
CHEMBL1185
|
1997 |
|
|
FENOLDOPAM
CHEMBL588
|
1997 |
|
|
SERTINDOLE
CHEMBL12713
|
1996 |
|
|
OLANZAPINE
CHEMBL715
|
1996 |
|
|
RISPERIDONE
CHEMBL85
|
1993 |
|
|
CLOZAPINE
CHEMBL42
|
1989 |
|
|
DOPAMINE
CHEMBL59
|
1974 |
|
|
HALOPERIDOL
CHEMBL54
|
1967 |
|
|
THIORIDAZINE
CHEMBL479
|
1962 |
|
|
CHLORPROMAZINE
CHEMBL71
|
1957 |